Investigative Alert: Pomerantz Law Firm Looks Into Altimmune Investor Claims Amid Stock Drop
Investigative Alert: Pomerantz Law Firm Looks Into Altimmune Investor Claims
On July 7, 2025, Pomerantz LLP announced an investigation on behalf of Altimmune, Inc. investors following alarming developments in the company's recent performance. This growing concern arises particularly after Altimmune, which trades on NASDAQ under the symbol ALT, saw a significant decline in its stock price.
Background of the Investigation
The investigation seeks to determine whether Altimmune and certain officers or directors may have engaged in securities fraud or other illicit business practices. Investors affected by these circumstances are encouraged to contact Pomerantz directly for further information.
Recent Developments
On June 26, 2025, Altimmune made headlines by releasing the topline results from its second Phoenix-style phase 2b clinical trial (IMPACT trial) targeting metabolic dysfunction-associated steatohepatitis (MASH). The company's press release indicated
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.